S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10

Halozyme Therapeutics Price Target, Predictions & Analyst Ratings

-0.38 (-1.17%)
(As of 01/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
962,260 shs
Average Volume
1.02 million shs
Market Capitalization
$4.50 billion
P/E Ratio
Dividend Yield

Halozyme Therapeutics (NASDAQ:HALO) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Based on 5 Analyst Ratings

Analyst Price Target Consensus

58.74% Upside

High PT$58.00
Average PT$50.75
Low PT$43.00
1/28/21 to 1/28/22
1 Month Ago
12/29/20 to 12/29/21
3 Months Ago
10/30/20 to 10/30/21
1 Year Ago
1/29/20 to 1/28/21
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$50.75$55.33$54.14$42.45
Price Target Upside58.74% Upside32.87% Upside24.00% Upside22.19% Upside
Get Halozyme Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Halozyme Therapeutics (NASDAQ:HALO) vs. Its Competitors

TypeHalozyme TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingBuyBuyBuy
Price Target Upside58.74% Upside313.54% Upside19.69% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
Community Rating
Outperform Votes
Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes

Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/26/2022Piper Sandler
Lower Price Target$46.00 ➝ $43.00+28.24%
12/10/2021JMP Securities
Jason Butler
Reiterated RatingBuy$54.00+53.58%
11/24/2021Wells Fargo & Company
Lower Price TargetOverweight$60.00 ➝ $58.00+65.67%
11/3/2021SVB Leerink
G. Porges
Lower Price TargetOutperform$50.00 ➝ $48.00+21.55%
6/14/2021Evercore ISI
Initiated CoverageOutperform
1/25/2021BMO Capital Markets
Boost Price TargetOutperform$56.00 ➝ $65.00+31.31%
Boost Price TargetBuy$46.00 ➝ $59.00+23.77%
12/17/2020Berenberg Bank
Initiated CoverageBuy$50.00+21.62%
12/11/2020Smith Barney Citigroup
Boost Price Target$29.00 ➝ $41.00+1.33%
9/14/2020JPMorgan Chase & Co.
Initiated CoverageOverweight
Boost Price TargetNeutral$18.00 ➝ $26.00+13.94%
5/4/2020Cantor Fitzgerald
Charles Duncan
Boost Price TargetOverweight$35.00 ➝ $39.00+68.32%
Boost Price TargetEqual Weight$16.00 ➝ $20.00-5.62%
1/8/2020The Goldman Sachs Group
Initiated CoverageBuy$24.00+34.68%
(Data available from 1/28/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings Frequently Asked Questions

What is Halozyme Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Halozyme Therapeutics stock is Buy based on the current 1 hold rating and 4 buy ratings for HALO. The average twelve-month price target for Halozyme Therapeutics is $50.75 with a high price target of $58.00 and a low price target of $43.00. Learn more on HALO's analyst rating history

Do Wall Street analysts like Halozyme Therapeutics more than its competitors?

Analysts like Halozyme Therapeutics stock more than the stock of other Medical companies. The consensus rating score for Halozyme Therapeutics is 2.80 while the average consensus rating score for medical companies is 2.73. Learn more on how HALO compares to other companies

Do MarketBeat users like Halozyme Therapeutics more than its competitors?

MarketBeat users like Halozyme Therapeutics stock more than the stock of other Medical companies. 69.49% of MarketBeat users gave Halozyme Therapeutics an outperform vote while medical companies recieve an average of 67.57% outperform votes by MarketBeat users.

Does Halozyme Therapeutics's stock price have much upside?

According to analysts, Halozyme Therapeutics's stock has a predicted upside of 37.22% based on their 12-month price targets.

What analysts cover Halozyme Therapeutics?

Halozyme Therapeutics has been rated by JMP Securities, Piper Sandler, SVB Leerink, and Wells Fargo & Company in the past 90 days.

This page was last updated on 1/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.